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Introduction
Protein–protein interactions are widely regarded as pivotal to
cell regulation and are increasingly of interest as targets in
small-molecule drug discovery.[1] Disruption of protein–protein
interactions can be challenging; however, some progress has
been made in this area. For example, the interaction between
p53 and MDM2, which involves a comparatively small binding
interface, can be blocked by several chemical classes of small
molecules, some of which have progressed to the clinical in-
vestigation stage.[2] Similarly, small-molecule BH3 domain mim-
etics block the interaction of anti-apoptotic Bcl2 family mem-
bers with BH3-domain-containing pro-apoptotic proteins.[3]
These compounds show tumour growth inhibition in tumour
models and have progressed to early clinical-stage research.[3]
Finally, various investigational small-molecule blockers have
been reported for the protein interaction between VLA4–
VCAM,[4] B7.1–CD28,[5] oestrogen-related receptor-a and its co-
activator,[6] and protein kinase C-iota and its effector PAR6.[7]
The interaction between S100 proteins and their targets has
been implicated in numerous biological and pathological pro-
cesses. The principle function of S100 proteins is regulation of
the localisation and activity of other proteins by direct pro-
tein–protein interactions. Some of these interactions have po-
tential therapeutic relevance. Recent genetic deletion studies
have implicated both S100A10 and its binding partner annexin
A2 in the process of neo-angiogenesis.[8] This parallel pheno-
type suggests these two partners may form a physical complex
to regulate this process. Small-molecule blockers of the inter-
action would greatly aid the further investigation of this idea.
At the molecular level, the interaction is very well characterised
both by mutagenesis and crystallography, involving a small
and largely hydrophobic binding area.[9] Two S100A10 mole-
cules form a dimeric structure that yields two binding pockets,
each of which accommodates the 14-residue N-terminal region
of annexin A2. Using a structure-based virtual high-throughput
docking approach, we previously identified several clusters of
small molecules that dock into the annexin A2 binding pocket
on S100A10.[10] Biochemical screening of these showed that
substituted 4-aroyl-3-hydroxy-5-phenyl-1H-pyrrol-2(5H)-one an-
alogues are capable of inhibiting the binding between
S100A10 and annexin A2.[10] In the present study we sought to
provide further evidence that this protein interaction can be
targeted with small-molecule blockers. To do so, we used
a ligand-guided method as an alternative to the above
random docking approach. The binding pose of the cognate
annexin A2 N terminus into the S100A10 dimer is very well
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characterised, and we used the topological arrangement of
key chemical features in the annexin A2 N terminus known to
be important for interacting with the S100A10 protein, to
design a 3D pharmacophore. We screened a library of com-
pounds against this 3D pharmacophore and identified mole-
cules that match these features and their topology. These were
tested for inhibition of the interaction between S100A10 and
the annexin A2 N terminus. Thus we established that substitut-
ed 1,2,4-triazole analogues are able to compete with the bind-
ing of the annexin A2 N terminus to S100A10.
Results
3D pharmacophore generation
Taking into account the crystal structure model of the complex
between S100A10 and the annexin A2 N terminus and the
effect of modification of the annexin A2 N terminus on its in-
teraction with S100A10,[9] a pharmacophoric query was con-
structed. Within the annexin A2 N terminus, the valine residue
at position 3 and the leucine residues at positions 7 and 10 are
crucial for binding with S100A10 as is the N-acetyl group of
the N-terminal serine residue. Contact surface analysis indicates
that the acetyl group, as well as the Val3 and Leu7 residues
point into the pocket (Figure 1A, represented as yellow sticks).
The acetyl group occupies a relatively small hydrophilic pocket
(acetyl pocket, Figure 1A) composed of Pro1, Ser2, His6, and
Glu9 of molecule B of the S100A10 dimer. The isopropyl side
chain of Val3 is accommodated in a hydrophobic pocket,
which is also solvent accessible and is composed of Cys82 of
S100A10 molecule A, and Met8, Met12, and Glu9 of S100A10
molecule B (valine pocket, Figure 1A). The side chain of Leu7
also partly occupies another hydrophobic cavity composed of
Phe38, Pro39, Gly40, Phe41, and Leu78 of S100A10 molecule A,
Figure 1. A) Binding pose of the annexin A2 N-terminal peptide (represented as lines with the secondary helical structure superimposed) within the binding
site of S100A10. The isopropyl side chain of Val3 (yellow sticks) is directed into the valine pocket. The side chain of Leu7 (yellow sticks) partly occupies the
leucine pocket. The acetyl group at Ser1 (yellow sticks) occupies the acetyl pocket. B) Schematic representation of the pharmacophoric query. Two hydropho-
bic features (Hydrophobic1_Leu, Hydrophobic2_Val) are shown as red spheres, whilst the carbonyl group (C=O, Markush atom) is represented by a magenta
sphere. Hydrogen bonds are defined as vectors (shown as yellow lines) from the donor atom of the peptide to the corresponding acceptor atom in the recep-
tor and vice-versa. Asterisks indicate the centres of the spheres. Hydrogen bond donor features of the peptide (LD_16_Thr2, LD_11_Thr2, LD_255_Ser1, LD_
31_His4) are shown as grey spheres. Hydrogen bond acceptor features of the receptor (S100A10) are shown in yellow (RA_805_Glu9B, RA_804_Glu9B, RA_
773_Glu5B, RA_331_Phe41A). For Ser11 of the peptide, the side chain OH group acts as hydrogen bond donor as well as hydrogen bond acceptor feature
(LD/LA_87_Ser11), represented as a green sphere. The hydrogen bond donor atom feature (RD_372_Gln45A) of the receptor is shown as an indigo sphere.
The hydrogen bond acceptor feature (LA_78_Leu10) of the peptide is shown as a cyan sphere. For clarity, the receptor site constraints are not shown in the
query (see also panel D). C) Overlay of the pharmacophore query generated under B and the annexin N-terminal peptide in its docked pose as shown under
A. Amino acids associated with the pharmacophoric features are indicated in blue (receptor features) or black (ligand features). D) Representation of the phar-
macophore query in the annexin N terminus binding groove of S100A10. The images in panels A and D were generated using SYBYL-X Molcad with the mo-
lecular surface of S100A10 coloured according to lipophilic potential. Images in panels B and C were generated with the SYBYL-X UNITY module.
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and Glu5 and Met8 of S100A10 molecule B (leucine pocket,
Figure 1A).
The above hydrophobic contacts of Val3 and Leu7 are repre-
sented by hydrophobic features in the pharmacophore query
(Figure 1B–D) and include six- and five-membered rings, tert-
butyl, cyclopropyl, isobutyl, and other aliphatic chains. Based
on the size of the cavity available within the binding pocket,
a spatial constraint with a tolerance of 1.5  was added to the
Leu7 hydrophobic feature, and a spatial constraint with a toler-
ance of 1.25  was added to the Val3 hydrophobic feature.
This resulted in spherical hydrophobic features (red, Fig-
ure 1B–D) reflecting the tolerance in the 3D position. A car-
bonyl group, representing the N-acetyl group of annexin A2,
was defined as a third pharmacophoric feature. Because the
relevant pocket is relatively small, a spatial point constraint
with a tolerance of 0.75  was added to the carbon atom (ma-
genta sphere, Figure 1B–D). This feature was further enhanced
by employing Markush carbonyl atom definition, which allows
compounds with specific functional groups at the acetyl
pocket. These include -COCH3, -CONH2 -COCH2CH3, -COOCH3,
-COOCH2CH3, -NHCOCH3, -NHCOCH2CH3, -NHCOOCH3,
-NHCOOCH2CH3, -NHCONH2, -CH2COOH, and -NHCOOH.
Hydrogen bond interactions are represented in the query in
the form of hydrogen bond donor and acceptor features (Fig-
ure 1B–D). The side chain hydroxy group (LD_16_Thr2, grey
sphere) and the backbone NH group (LD_11_Thr2, grey
sphere) of Thr2 undergo hydrogen bond donor interactions
with the carboxyl group (RA_804_Glu9B, yellow sphere) of the
Glu9 residue in S100A10 molecule B. The backbone NH group
of Ser1 (LD_255_Ser1, grey sphere) forms hydrogen bond
donor interactions with the side-chain carboxyl (RA_805_Glu9B
and RA_804_Glu9B yellow spheres) of Glu9 in S100A10 mole-
cule B. The ring NH group of His4 (LD_31_His4, grey sphere)
forms a hydrogen bond donor interaction with the carboxyl
group (RA_773_Glu5B, yellow sphere) of Glu5 in S100A10 mol-
ecule B. Furthermore, the side-chain hydroxy group (LD_87_
Ser11, green sphere) of Ser11 forms a hydrogen bond donor
interaction with the backbone carboxyl oxygen (RA_331_
Phe41A, yellow sphere) of Phe41 in S100A10 molecule A and
hydrogen bond acceptor interaction (LA_87_Ser11, green
sphere) with the side chain carboxamide NH2 (RD_372_Gln45A,
indigo sphere) of Gln45 in S100A10 molecule A. The backbone
carbonyl oxygen (LA_78_Leu10, cyan sphere) of Leu10 under-
goes a hydrogen bond acceptor interaction with the side-
chain carboxamide NH2 (RD_372_Gln45A, indigo sphere) of
Gln45 in S100A10 molecule A. A spatial constraint with a toler-
ance of 1.0  was added to all hydrogen bond donor and ac-
ceptor features except for the hydrogen bond donor feature of
Ser1, for which a tolerance of 0.25  was added in order to
avoid the overlap of its spatial constraint with the adjacent car-
bonyl atom spatial constraint. A final significant feature includ-
ed in the query was the receptor site constraint. This was
added in the form of multiple excluded volume spheres with
a van der Waals scaling factor of 0.5  (not shown for clarity).
For a compound to be considered as a hit, it should match the
query features without colliding with multiple excluded
volume spheres that represent the protein surface.
Computational screening for pharmacophore matches
A 3D database containing 704511 structurally diverse com-
pounds was generated from the Zinc database[11] (Asinex and
ChemBridge vendors) using the following five molecular filters:
1) Mr range: 150–600 Da, 2) hydrogen bond donors: <7, 3) hy-
drogen bond acceptors : <14, 4) XlogP : <5, and 5) rotatable
bonds: <12. For each molecule, a single conformation was
stored in the 3D database. A UNITY flexible 3D search was
then performed on the 3D pharmacophore model using the
direct tweak algorithm, which adjusts the rotatable bonds of
the molecules to match the 3D pharmacophoric model as
closely as possible. The search was designed to match the
most significant hydrophobic features derived from the leucine
and valine pockets as well as the Markush carbonyl definition
with a receptor site constraint in place. In addition, the search
was refined to allow partial matching of hydrogen bonding
donor or acceptor features, such that for a molecule to be con-
sidered a hit, a minimum of one and a maximum of five hydro-
gen bonding features were required to fit. The entire UNITY
3D database search of the 704511 compounds was performed
directly on an Intel I7-based LINUX system. The time taken for
the search was ~120 h. This search returned 568 hits.
These hits were ranked based on their best-fit values gener-
ated from the 3D search. The fit values reflect the agreement
of the hit compounds with the pharmacophore model, with
higher fit values indicating better mapping of the hit com-
pound onto the pharmacophore model. The fit values ranged
from 62 to 8. The hit compounds were also docked using the
Genetic Optimisation for Ligand Docking (GOLD) program[12] in
standard parameter mode into the defined annexin A2 binding
pocket of the S100A10 receptor. Docked compounds were
ranked based on the GOLD score, which represents the sum of
receptor–ligand hydrogen bonding energy, van der Waals
energy, torsional energy, and hydrophobic interaction energies
and ranged from 66 to 36. Higher GOLD scores indicate better
binding interaction of the compounds with the S100A10 re-
ceptor. The docking procedure for the 568 hit compounds was
carried out using the GOLD (V3.0.1) docking program; calcula-
tions required ~1 h running on 32 dual AMD Opteron 248
servers. A total of 190 hits that were selected based on best-fit
values, higher GOLD fitness scores, and a good binding mode
in accordance with our pharmacophore query were purchased.
Identification and analysis of inhibitory compounds
Hits were tested for the inhibition of the interaction between
S100A10 and the annexin A2 N terminus in a competitive fluo-
rescent binding assay.[13] Each compound was tested in quad-
ruplicate at a single concentration of 10 mm. Compounds
showing inhibitory activity (defined as signal deviating by >3
standard deviations from the no-compound control) were se-
lected for repeat testing at the same concentration. Seven
compounds showed consistent levels of inhibition, and these
were taken forward for IC50 determination. Furthermore, these
compounds were analysed in a counterscreen, which measures
a nonrelated protein interaction using the same assay format.
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Three compounds showed activity in the primary assay, but
not in the counterscreen assay (Figure 2A), whilst four com-
pounds showed overlap in activity between the two assays
(Figure 2B for an example: a compound from the ChemBridge
catalogue with vendor number 7832669 and Zinc database
number ZINC02858054). The latter compounds could represent
promiscuous protein interaction blockers, or compounds that
in some way interfere with the fluorescence signal. The struc-
tures of three confirmed hit compounds are shown in Figure 3.
Interestingly, all hit compounds featured the same acetamide
side chain, suggesting a potentially significant contribution of
this group to binding interactions. Analysis of the mapping of
the pharmacophore onto these inhibitors indicates that the hy-
drophobic feature associated with the leucine pocket mapped
onto one of the phenyl rings of the naphthyl ring system (1a),
onto the phenyl moiety of the ortho-toluyl group (1b), or the
phenyl moiety of the para-anisole group (1c) (Figure 4, top
panels). The hydrophobic feature associated with the valine
pocket mapped onto the N4-phenyl rings in compounds 1a
and 1c, whereas in the case of compound 1b it overlapped
with the ortho-ethyl group of the N4-phenyl ring. In the case
of compounds 1a, 1b, and 1c the amide group matched the
Markush atom definition with the NH2 group locating to the
hydrogen bond donor feature, within hydrogen bonding dis-
tance to the carboxyl group of Glu9 in S100A10 molecule B.
Importantly, the UNITY-generated conformations of com-
pounds 1a, 1b, and 1c mapped onto the 3D pharmacophoric
query without clashing with the receptor site (multiple exclud-
ed volume spheres).
The binding modes predicted by GOLD for compounds 1a,
1b, and 1c are in good agreement with their UNITY-generated
conformations (Figure 4, bottom panels). The predicted bind-
ing modes indicate that the substituted aromatic rings closely
mimic Val3 and Leu7 in annexin A2, interacting with the hydro-
phobic pockets of S100A10. In case of compounds 1a and 1b
the NH2 group of the amide side chain at the acetyl pocket is
in close proximity to Glu9 in S100A10 molecule B, suggesting
the possibility of hydrogen bond interactions taking place. In
compound 1c both the NH2 group of the amide and the sec-
ondary amine group undergo hydrogen bond interactions
with the carboxyl groups of S100A10 B-chain Glu9 and
S100A10 B-chain Glu5, respectively. This appears to mimic the
hydrogen bond interaction of Glu9 and Glu5 residues of the
receptor with the annexin A2 N-terminal peptide in the crystal
structure. Considering the inhibitory potential of these triazole
compounds 1a (66 mm), 1b (24 mm), and 1c (90 mm) we syn-
thesised a series of analogues and investigated their structure–
activity relationships.
Synthesis of substituted 1,2,4-triazoles
The required disubstituted 1,2,4-triazoles 1b, 1c, and 7a–
i were prepared as depicted in Scheme 1. The substituted
acetic acid ethyl ester 3a (X=O) was prepared by treating
ortho-cresol 2a with bromoethyl acetate in the presence of
sodium hydride in N,N-dimethylformamide. The substituted
acetic acid ethyl esters 3b–c (X=NH) were prepared by treat-
ing substituted anilines 2b–c with bromoethyl acetate in the
presence of triethylamine in ethanol. Subsequent reaction of
ethyl esters 3a–c (X=O or NH) with hydrazine monohydrate
Figure 2. Inhibitory activity of A) compound 1b and B) compound 7832669
(ChemBridge reference number; also referred to as ZINC02858054). Both
compounds were tested for inhibition of the interaction between S100A10
and the annexin A2 N terminus (* and ~) or for inhibition of a non-target
protein interaction (* and ~) as explained in the Results and Experimental
Section. Data points represent the average SEM of four observations.
Figure 3. Structures and IC50 values of hit compounds.
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gave the corresponding acyl hydrazides 4a–c in good to excel-
lent yields.[14] Condensation of the acyl hydrazides 4a–c with
substituted aromatic or aliphatic isothiocyanates 5, followed
by base-catalysed cyclisation, resulted in 4-substituted 3-mer-
capto-1,2,4-triazole analogues 6a–k. Treatment of these inter-
mediates with 2-bromoacetamide in the presence of potassi-
um carbonate resulted in the formation of disubstituted 1,2,4-
triazole analogues 1b–c and 7a–i.[15]
Structure–activity relationships
The 1,2,4-triazole compounds synthesised were
screened using an in vitro FRET-based competitive
binding assay to evaluate their ability to inhibit the
interaction between S100A10 and an annexin A2 N-
terminal peptide.[13] An IC50 value was obtained for
each compound from nonlinear regression analysis
(GraphPad Prism, variable slope) with top and
bottom constraints of 100 and 0%, respectively.
To investigate the contribution of the phenyl ring
at the N4 position of the 1,2,4-triazole ring system to
the inhibition of binding, a set of analogues with X=
O (7a–g) was prepared (Table 1). An unsubstituted
phenyl ring at the N4-position (7a, IC50=230 mm)
showed very low potency, suggesting that the aro-
matic ring alone is insufficient for inhibitory activity
and that the substitution pattern is important. Re-
placement of the N4 ring system with a flexible ali-
phatic methoxyethyl group (yielding 7c) abolished
activity altogether, reinforcing the notion that a substituted ar-
omatic ring system at this position is important for inhibition
of binding. With reference to compound 7a (230 mm), the
effect of various substitutions on the phenyl ring was assessed.
An ortho-ethyl substitution (1b, 24 mm) showed increased po-
tency, possibly due to the introduction of a conformational re-
striction imposed on the phenyl group. However, introduction
of a bulky chloro group at the ortho position (7b, 176 mm) was
Figure 4. Top panels : Mapping of the 3D pharmacophore query onto the inhibitors (1a–c) ; the fit values were 30, 20, and 25, respectively. The compounds
showed good agreement between their UNITY-generated conformations and the conformations of the binding pose predicted by GOLD (bottom panels).
GOLD scores of compounds 1a–c were 54, 51, and 54, respectively. Mapping was carried out using the SYBYL-X UNITY module, and the binding poses were
generated with the GOLD docking program. The molecular surface of the S100A10 is coloured according to lipophilic potential.
Scheme 1. Synthesis of 2-(4-substituted-5-substituted phenyl oxy/amino methyl-4H-
[1,2,4]triazol-3-ylsulfanyl)acetamides. Reagents and conditions : a) X=O: DMF, under N2,
NaH, 60 min, RT followed by bromoethyl acetate, 30 min, RT, then H2O; X=NH: bro-
moethyl acetate, Et3N, EtOH, reflux, 30–75 min; b) H2NNH2·H2O, EtOH, reflux, 5 h to over-
night; c) EtOH/reflux, overnight; d) 1.5m KOH (base-catalysed cyclisation), 5n HCl; e) 2-
bromoactamide, K2CO3, DMF, 45 8C, overnight, then H2O.
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less effective in terms of inhibitory activity. Introduction of
a para-methyl group (7d, 88 mm) showed a moderate increase
in inhibitory activity, but a chloro group at the para position
(7e, 710 mm) resulted in a profound loss of activity. Introduc-
tion of a more polar methoxy substituent at the para position
(7 f, 122 mm) did not affect the inhibition of binding, but a com-
pound with an isopropyl side chain at the para position (7g,
27 mm) was comparatively potent. This may be due to the fact
that the phenyl ring projects towards the valine pocket, with
the isopropyl group mimicking the valine side chain of the an-
nexin peptide.
Because one of the original hit compounds (1c) contains
X=NH, a small set of analogues with X=NH were prepared,
and substituents at the N4 and R1 positions of the 1,2,4-triazole
ring system were varied (Table 1). Compound 1c (90 mm) with
a para-methylphenyl substituent at the N4 position and
a para-methoxy substituent at the R1 position showed weak in-
hibitory activity. Replacement of both para-methyl and me-
thoxy substituents in 1c with chloro and methyl substituents
(7h) resulted in loss of activity. Replacement of the para-
methyl group in 1c with a bulkier ortho-ethyl group (7 i,
75 mm) largely retained activity. These patterns are, to an
extent, reminiscent of those observed in the X=O analogues,
with a para-chloro substituent being highly disfavoured (7e,
710 mm ; 7h, inactive), and an ortho-ethyl group supporting in-
hibitory activity of these compounds (1b, 24 mm ; 7 i, 75 mm).
The NH group may act as a hydrogen bond donor to the car-
bonyl oxygen of glutamic acid of the S100A10 protein. Refer-
ence to the modelled binding pose of 1c (Figure 4), in which
the NH group is hydrogen bonded to the carbonyl oxygen
atom of glutamic acid of S100A10, supports this notion. In this
regard, the loss in activity observed for compound 7h was un-
expected.
As mentioned above, a carbonyl group (representing the
peptide N-acetyl) was defined as the third pharmacophoric fea-
ture, and a range of various functional groups were allowed at
this part of the query. Rather strikingly, all three hit compounds
contained the same acetamide side chain mapping onto the
pharmacophore, suggesting a potentially significant contribu-
tion of this group for binding interactions. This was investigat-
ed further by truncating the sulfanylacetamide side chain to
the corresponding thiol. This resulted in a sixfold decrease in
binding activity of compound 1b, 24 mm (6e, 275 mm), a three-
fold decrease in binding activity of compound 7g, 27 mm (6k,
68 mm) and a twofold further decrease in binding activity of
the already very weak blocker 7a, 230 mm (6d, 481 mm). For
compounds 7d, 88 mm and 7 f, 122 mm (yielding 6 i and j, re-
spectively), this modification resulted in conversion into partial
blockers of the interaction, inhibiting <50% of the binding.
Thus the acetamide side chain appears to make an important
contribution to the activity of these compounds, possibly by
acting as a hydrogen bond donor to its receptor. Consistent
with this trend, truncation of the sulfanyl acetamide side chain
of compound 7 i (75 mm) to the thiol 6a resulted in complete
loss of activity. However, similar truncation compounds 7c and
7h (both inactive) resulted in moderately active compounds
(6g, 117 mm and 6c, 115 mm respectively), whilst this modifica-
tion is associated with a small increase in potency for com-
pound 1c, 90 mm (6b, 35 mm) and a large gain in potency for
7e, 710 mm (6h, 23 mm).
Discussion
We have presented a ligand-based virtual screening approach
to identify inhibitors of the protein interaction between
annexin A2 and S100A10. Based on the binding pose of the
annexin A2 N terminus in S100A10, a Markush carbonyl atom,
hydrophobic and hydrogen bond interactions, along with spa-
tial and receptor constraints, were established as key pharma-
cophoric features that were translated into a 3D pharmaco-
phore. Screening of >700000 compounds against this phar-
macophore resulted in the identification of 1,2,4-triazole com-
pounds 1a–c as novel genuine inhibitors of the S100A10–an-
nexin A2 interaction. The GOLD-predicted binding modes of
these compounds were analysed, revealing close similarity to
the UNITY-predicted binding modes. A set of 22 compounds
were synthesised, and SARs were explored. Four compounds
(1b, 7g, 6b, 6h) showed inhibitory activity <50 mm and an-
Table 1. Structure–activity relationships of 2-(4-substituted-5-substituted
phenyl oxy/amino methyl-4H-[1,2,4]triazol-3-ylsulfanyl)acetamides.
Compd Type X R2 R4 R1 IC50 [mm]
[a]
7a I O H H 2-Me 230
1b I O Et H 2-Me 24
7b I O Cl H 2-Me 176
7c – – – – – NA
7d I O H Me 2-Me 88
7e I O H Cl 2-Me 710
7 f I O H OMe 2-Me 122
7g I O H iPr 2-Me 27
7h I NH H Cl 4-Me NA
1c I NH H Me 4-OMe 90
7 i I NH Et H 4-OMe 75
6a II NH Et H 4-OMe NA
6b II NH H Me 4-OMe 35
6c II NH H Cl 4-Me 115
6d II O H H 2-Me 481
6e II O Et H 2-Me 275
6 f II O Cl H 2-Me 83
6g – – – – – 117
6h II O H Cl 2-Me 23
6 i II O H Me 2-Me partial
6 j II O H OMe 2-Me partial
6k II O H iPr 2-Me 68
[a] NA: no inhibition was observed; partial : compound behaved as partial
blocker of binding.
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other set of six compounds (1a, 1c, 7d, 7 i, 6 f, 6k) showed in-
hibitory activity <100 mm. Overall, some interesting SAR pat-
terns emerged, with hydrophobic features favoured at the N4-
position of the 1,2,4-triazole ring system and an acetamide
side chain making contributions to binding in the majority of
compounds. Thus an approach involving generation of a phar-
macophoric query based on the peptide binding pose of an-
nexin A2 in the S100A10 dimer and subsequent biochemical
screening of candidate pharmacophore matches, has yielded
small-molecule blockers that could be developed further in
terms of inhibitory potential and drug-like properties.
Previous work in our research group identified substituted
pyrrol-2-ones as potential blockers of the interaction of annexi-
n A2 with S100A10,[10] using a random docking approach to
computational pre-selection of the compounds that were
tested biochemically. This approach interrogates compounds
for their geometric complementarity with the target receptor
binding pocket, whilst the 3D pharmacophore design method
used in the current study selects compounds for similarities to
specific chemico-topological features of the ligand that are as-
sociated with binding.[16] For both methods, a static 3D co-crys-
tal model[9b] was used as starting point for the design process.
However, flexibility of the system will affect what the binding
site will actually look like when the designed ligands meet the
protein in the biochemical assay system.[16] Uncertainties in the
prediction could explain why different scaffolds were identified
in the two studies, and suggests the usefulness of employing
multiple strategies for hit finding, as previously suggested for
other drug targets.[17]
Some of the pyrrol-2-ones[10] appeared to be more potent
than the most potent 1,2,4 triazoles described here. The rea-
sons are unclear, and the number of compounds tested in
either study precludes a generalised conclusion. Potency differ-
ences observed between the studies may be due to the way
the parameters for curve fitting of the biochemical data were
set, which differed slightly. However, reanalysis using the same
parameter settings still showed the pyrrol-2-ones to be more
potent than the 1,2,4 triazoles described herein.
There are other protein–protein interactions for which small-
molecule blockers have been identified. Notable amongst
these are two protein interactions implicated in cancer biology,
namely the interaction between MDM2 and p53,[2,18] and the
interaction between Bcl2 and Bak.[3] Like annexin A2, p53 and
Bak contain a small helical structure that docks into a well-de-
fined groove-like feature on the surface of the respective bind-
ing partners. Thus whilst protein–protein interactions may be
considered difficult targets for small-molecule inhibitors, this
cannot be generalised, and certain interactions with shared
features in terms of the binding site appear to be more ame-
nable to small-molecule inhibition than others. For the interac-
tion between S100A10 and annexin A2, the proposed 1,2,4-tri-
azole compounds will be useful for further biological assess-
ment of the function of this complex. Furthermore, they may




S100A10–annexin A2 N-terminal peptide complex : The Tripos
(SYBYL-X 1.0) Biopolymer module was used for the protein struc-
ture preparation process. Two chain termini (Lys91, Pro1) of each
monomer of the S100A10 and Ser11 of each annexin A2 N-terminal
peptide were charged. Hydrogen atoms were added, and Amber 7
FF99 charges were assigned to the complex. The side chain amides
of Gln45 and Gln60 were re-oriented to maximise hydrogen bond-
ing. The complex was then subjected to stepwise energy minimisa-
tion. The parameters used were Amber 7 FF99 force fields, Powell’s
minimisation method, 0.5 kcalmol1 gradient, no initial optimisa-
tion was performed, and a maximum of 5000 iterations were used.
A centroid was defined by a set of atoms within 5  of the annexi-
n A2 peptide, and the peptide was then extracted from the com-
plex. Water molecules were deleted before docking.
UNITY search : The UNITY module of SYBYL-X (V1.0) was used for
the design of a highly focused pharmacophoric query. The query
was directly built in UNITY from the energy-minimised co-crystal
structure of S100A10–annexin A2 N-terminal peptide as described
in the results section, using relevant features (hydrogen bond ac-
ceptor atom, hydrogen bond donor atom, acceptor site, and donor
site to specify the directionality of the hydrogen bond, hydropho-
bic features) and constraints (distance, spatial point, and receptor
site constraints). UNITY flex searches were performed on 3D com-
pound databases with a single conformational representation of
each compound, using the direct tweak algorithm to match the
conformation of the molecule with the defined pharmacophoric
query. Hits were generated based on how well the compounds
matched the query.
GOLD (V3.0.1) docking studies : Ten docking runs were performed
on each molecule and allowed the early termination of the dock-
ing runs if the top three solutions were within the 1.5  RMSD of
each other. During the run, 100000 genetic algorithm (GA) opera-
tions were performed on a single population of 100 individuals.
Operator weights for the crossover, mutation, migration (95, 95,
and 10 respectively) hydrogen bonding (4.0 ), and van der Waals
(2.5 ) parameters were set as default value throughout the dock-
ing. An active site radius value of 12  was found to be optimum.
Flipping was not allowed for those ligands that have ring-NHR and
ring-NHR1R2 groups in order to avoid the addition of large torsional
energy penalties to the total fitness scores.
Biology
Fluorescence screening assay : Routine assessment of compound ac-
tivity was performed as described by Li et al.[13] Briefly, a Cy5-la-
belled S100A10 tracer was developed, and binding of a Cy3-la-
belled annexin A2(1–14) peptide ligand was assessed using a fluo-
rescence resonance energy transfer (FRET) readout. Assays were
carried out in Nunc black non-treated 384-well plates at 20 8C in
50 mL 137 mm NaCl, 2.7 mm KCl, 4.3 mm Na2HPO4, 1.47 mm KH2PO4
pH 7.4 containing 2 mm 1,4-dithiothreitol. All incubations were per-
formed in quadruplicate. Compounds, peptide, and buffer controls
were added to the wells in a 10 mL volume in 5% DMSO. Cy5-la-
belled S100A10 tracer (407 nm) and Cy3-labelled annexin A2(1–14)
peptide ligand (1.33 mm) were pre-incubated for 5 min at 20 8C,
and 40 mL of the preformed complex was then added to the wells
and mixed for 10 s to yield a final DMSO concentration of 1%.
After 5 min incubation at 20 8C, readings were taken on a Perkin-
Elmer Envision instrument by excitation at 488 nm and emission at
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695 nm. As controls, each screening plate contained the individual
labelled proteins, as well as the two protein partners with and
without the unlabelled annexin A2(1–14) competitor (12.8 mm ; all
in quadruplicate).
FRET was calculated by measuring the fluorescence emission of co-
incubated S100A10–Cy5 and annexin A2(1–14)–Cy3 and subtract-
ing the same signal obtained in the presence of excess unlabelled
annexin A2(1–14) peptide. A counterscreen assay,[13] which meas-
ures the FRET signal from a Cy3-conjugated donkey anti-goat IgG
(4 mgmL1) onto a Cy5-labelled goat IgG (3 mgmL1), was used in
parallel to assess nonspecific interference with the fluorescence
readout. Compound binding was calculated as a percentage of un-
treated control, and data were analysed by nonlinear regression
(dose–response, variable slope) using GraphPad Prism Software
with top and bottom constraints at 100 and 0%, respectively
(unless otherwise discussed in the text).
Chemistry
General : All reagents were purchased directly from commercial
sources and were used as supplied unless otherwise stated. Melt-
ing points were measured with a Gallenkamp melting point appa-
ratus and are uncorrected. Accurate mass and nominal mass meas-
urements were performed using a Waters 2795-Micromass LCT
electrospray mass spectrometer. Infrared spectra were recorded on
an AVATAR 360 FTIR system. Samples were prepared as KBr discs
and scanned from 4000 to 500 cm1 (for compounds 7 i and 6a).
All NMR spectra were recorded in [D6]DMSO, with trimethylsilane
as an internal standard, using a Bruker ACS-120 instrument at
400 MHz (1H NMR) and 100.6 MHz (13C NMR). Chemical shifts (d) are
reported in ppm, and coupling constants (J) are given in Hz. Sig-
nals are represented by s (singlet), d (doublet), t (triplet), q (quar-
tet), m (multiplet), bs (broad singlet), dd (double doublet), and td
(triple doublet). Thin-layer chromatography was performed using
aluminum-backed silica gel 60 plates (0.20 mm layer), the ascend-
ing technique was used with a variety of solvents. Visualisation
was by UV light at either l 254 or 365 nm.
o-Tolyloxyacetic acid ethyl ester (3a): To a solution of o-cresol
(525 mL, 5.0 mmol, 1.0 equiv) in DMF (15 mL) under N2 was added
NaH (300 mg, 7.5 mmol, 1.5 equiv). The reaction was allowed to
stir for 60 min at RT under N2. To this was added ethyl bromoace-
tate (566 mL, 5.0 mmol, 1.0 equiv), and the reaction mixture was al-
lowed to stir for 30 min. The reaction mixture was poured into
cold H2O (25 mL) and allowed to stand for 60 min. No precipitate
was observed. The aqueous phase was extracted with EtOAc, and
the EtOAc layer was dried (Na2SO4) and concentrated under re-
duced pressure to give product 3a as a pale-yellow oil (740 mg,
76% yield): Rf=0.44 (EtOAc/petroleum ether (PE), 1:6) ;
1H NMR
(400 MHz, [D6]DMSO): d=7.20–7.08 (2H, m, Ar-H), 6.86 (1H, td, J=
0.8, 7.4 Hz, Ar-H), 6.82 (1H, d, J=8.2 Hz, Ar-H), 4.78 (2H, s, CH2),
4.16 (2H, q, J=7.1 Hz, CH2-CH3), 2.20 (3H, s, CH3), 1.21 ppm (3H, t,
J=7.1 Hz, CH2-CH3) ;
13C NMR (100.6 MHz, [D6]DMSO): Cq: d=168.8,
155.8, 126; CH: 130.6, 126.8, 120.9, 111.4; CH2: 64.9, 60.5; CH3: 16.0,
14.0 ppm; HRMS (ES): m/z [M+H]+ calcd for C11H15O3: 195.0943,
found: 195.0962.
p-Tolylaminoacetic acid ethyl ester (3b): To a solution of p-tolui-
dine (8.573 g, 80.0 mmol, 1.0 equiv) in EtOH (100 mL) was added
acetic acid sodium salt (9.844 g, 120.0 mmol, 1.5 equiv) and heated
at 90 8C for 5 min. To this was added ethyl bromoacetate
(9.052 mL, 80.0 mmol, 1.0 equiv) and the reaction mixture was
heated at reflux for 30 min. The reaction was cooled and concen-
trated under reduced pressure. The resulting residue was diluted
with H2O and extracted with EtOAc. The EtOAc layer was then
dried (Na2SO4) and concentrated under reduced pressure to result
in a reddish-yellow oil. This was slowly turned to a pale-yellow
solid under vacuum followed by recrystallisation from EtOH to fur-
nish product 3b as a pale-yellow crystalline solid (2.360 g, 16%
yield): Rf=0.25 (EtOAc/PE, 1:6) ; mp: 49–51 8C;
1H NMR (400 MHz,
[D6]DMSO): d=6.88 (2H, d, J=8.1 Hz, Ar-H), 6.45 (2H, d, J=8.4 Hz,
Ar-H), 5.73 (1H, t, J=6.4 Hz, NH), 4.10 (2H, q, J=7.1 Hz, CH2CH3),
3.83 (2H, d, J=6.5 Hz, CH2), 2.12 (3H, s, CH3), 1.19 ppm (3H, t, J=
7.1 Hz, CH2CH3) ;
13C NMR (100.6 MHz, [D6]DMSO): Cq: d=171.4,
145.8, 124.7; CH: 129.2, 112.2; CH2: 60.1, 45.0; CH3: 20.0, 14.1 ppm;
HRMS (ES): m/z [M+H]+ calcd for C11H16NO2: 194.1103, found:
194.1119.
(4-Methoxyphenylamino)acetic acid ethyl ester (3c): To a solution
of p-anisidine (9.951 g, 80.0 mmol, 1.0 equiv) in EtOH (150 mL) was
added Et3N (13.380 mL, 96.0 mmol, 1.2 equiv), and the reaction
mixture was stirred for 10 min. To this was added ethyl bromoace-
tate (9.052 mL, 80.0 mmol, 1.0 equiv), and the reaction mixture was
heated at reflux for 75 min. The reaction was cooled and concen-
trated under reduced pressure. The resulting residue was diluted
with H2O and extracted with EtOAc. Then EtOAc layer was dried
(Na2SO4) and concentrated under reduced pressure to give a red-
dish powder, which was further washed with Et2O/PE (2:1) to
afford product 3c as a pale-white powder (4.565 g, 27% yield): Rf=
0.28 (EtOAc/PE, 1:3) ; mp: 58–60 8C; 1H NMR (400 MHz, [D6]DMSO):
d=6.71 (2H, d, J=8.9 Hz, Ar-H), 6.50 (2H, d, J=8.9 Hz, Ar-H), 5.53
(1H, t, J=6.5 Hz, NH), 4.10 (2H, q, J=7.1 Hz, CH2CH3), 3.81 (2H, d,
J=6.5 Hz, CH2), 3.63 (3H, s, OCH3), 1.19 ppm (3H, t, J=7.1 Hz,
CH2CH3) ;
13C NMR (100.6 MHz, [D6]DMSO): Cq: d=171.5, 151.1,
142.2; CH: 114.5, 113.2; CH2: 60.2, 45.5; CH3: 55.3, 14.1 ppm; HRMS
(ES): m/z [M+H]+ calcd for C11H16NO3: 210.1052, found: 210.1320.
o-Tolyloxyacetic acid hydrazide (4a): To a solution of o-tolyloxy-
acetic acid ethyl ester (3a, 657 mg, 3.38 mmol, 1.0 equiv) in EtOH
(20 mL), a large excess of hydrazine (939 mL, 20.3 mmol, 6.0 equiv)
was added, and the reaction mixture was heated at reflux over-
night. The reaction mixture was cooled and concentrated under re-
duced pressure. The white precipitate obtained was washed with
EtOH/PE (1:3) to afford product 4a as a white crystalline solid
(367 mg, 60% yield): Rf=0.10 (EtOAc); mp: 114–116 8C;
1H NMR
(400 MHz, [D6]DMSO): d=9.20 (1H, s, NH), 7.18–7.06 (2H, m, Ar-H),
6.89–6.79 (2H, m, Ar-H), 4.49 (2H, s, CH2), 4.33 (2H, bs, NH2),
2.21 ppm (3H, s, CH3);
13C NMR (100.6 MHz, [D6]DMSO): Cq: d=
166.8, 156.0, 126.2; CH: 130.5, 126.8, 120.8, 111.3; CH2: 66.5; CH3:
16.1 ppm; HRMS (ES): m/z [M+H]+ calcd for C9H13N2O2: 181.0899,
found: 181.1532.
p-Tolylaminoacetic acid hydrazide (4b): The procedure was simi-
lar to the procedure for 4a except that p-tolylaminoacetic acid
ethyl ester (3b, 1.930 g, 10.0 mmol, 1.0 equiv) was used and the re-
action mixture and was heated at reflux for only 5 h. Product 4b
was isolated as a pale-white powder (1.34 g, 75% yield): Rf=0.23
(EtOAc/MeOH, 9:1) ; mp: 151–153 8C; 1H NMR (400 MHz, [D6]DMSO):
d=9.00 (1H, bs, NH-NH2), 6.89 (2H, d, J=8.1 Hz, Ar-H), 6.46 (2H, d,
J=8.5 Hz, Ar-H), 5.59 (1H, t, J=6.1 Hz, NH), 4.21 (2H, bs, NH2), 3.58
(2H, d, J=6.2 Hz, CH2), 2.14 ppm (3H, s, CH3);
13C NMR (100.6 MHz,
[D6]DMSO): Cq: d=169.5, 146.0, 124.7; CH: 129.2, 112.4; CH2: 45.7;
CH3: 20.0 ppm; HRMS (ES): m/z [M+H]
+ calcd for C9H14N3O:
180.1059, found: 180.1158.
(4-Methoxyphenylamino)acetic acid hydrazide (4c): The proce-
dure was similar to that for 4a except that (4-methoxyphenylami-
no)acetic acid ethyl ester (3c, 5.0 g, 23.9 mmol, 1.00 equiv) was
used in the reaction mixture. Product 4c was isolated as a white
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crystalline solid (3.986 g, 86% yield): Rf=0.20 (EtOAc/MeOH, 9:1);
mp: 115–117 8C; 1H NMR (400 MHz, [D6]DMSO): d=9.0 (1H, bs, NH-
NH2), 6.71 (2H, d, J=8.9 Hz, Ar-H), 6.51 (2H, d, J=8.9 Hz, Ar-H),
5.41 (1H, t, J=6.2 Hz, NH), 4.21 (2H, d, J=3.3 Hz, NH2), 3.63 (3H, s,
OCH3), 3.56 ppm (2H, d, J=6.2 Hz, CH2);
13C NMR (100.6 MHz,
[D6]DMSO): Cq: d=170.1, 151.6, 142.9; CH: 115.0, 113.8; CH2: 46.7;
CH3: 55.8 ppm; HRMS (ES): m/z [M+H]
+ calcd for C9H14N3O2:
196.1008, found: 196.1473.
4-(2-Ethylphenyl)-5-[(4-methoxyphenylamino)methyl]-4H-
[1,2,4]triazole-3-thiol (6a): To a solution of (4-methoxyphenylami-
no)acetic acid hydrazide (4c) (4.0 g, 20.489 mmol, 1.0 equiv) in
EtOH (150 mL) was added 2-ethylphenyl isothiocyanate (3.203 mL,
20.489 mmol, 1.0 equiv), and the reaction mixture was heated
under reflux overnight. The reaction was cooled and concentrated
under reduced pressure to result in a greasy yellow substance. To
this was added aqueous 1.5m KOH (50 mL) and heated at reflux
for 30 min, then cooled. The reaction was neutralised with 5n HCl
and extracted with EtOAc. The organic layer was dried (Na2SO4)
and concentrated under reduced pressure. The resulting yellow
solid was recrystallised from EtOH/MeOH (1:1) to afford the desired
product 6a as a white powder (2.246 g, 32% yield): Rf=0.65
(EtOAc); mp: 162–164 8C; 1H NMR (400 MHz, [D6]DMSO): d=13.82
(1H, s, SH or NH), 7.53–7.41 (2H, m, Ar-H), 7.36 (1H, td, J=1.6/1.7,
7.2/7.7 Hz, Ar-H), 7.27 (1H, dd, J=1.2, 7.8 Hz, Ar-H), 6.67 (2H, d, J=
8.9 Hz, Ar-H), 6.45 (2H, d, J=8.9 Hz, Ar-H), 5.40 (1H, t, J=5.9/
6.0 Hz, NH), 4.1–3.8 (2H, m, CH2), 3.61 (3H, s, OCH3), 2.4–2.2 (2H,
m, CH2-CH3), 1.07 ppm (3H, t, J=7.6 Hz, CH2-CH3) ;
13C NMR
(100.6 MHz, [D6]DMSO): Cq: d=168.1, 151.3, 150.7, 141.8, 141.6,
131.9; CH: 130.1, 128.9, 128.6, 126.9, 114.4, 113.4; CH2: 39.3, 23.1;
CH3: 55.2, 13.3 ppm; IR (KBr): n˜=3397 (NH), 3104, 3058 (CH of Ar),
2933, 2832 (CH from CH2), 1514 (C=N), 1308 cm
1 (C=S); HRMS
(ES): m/z [M+H]+ calcd for C18H21N4OS: 341.1358, found: 340.9735.
5-[(4-Methoxyphenylamino)methyl]-4-p-tolyl-4H-[1,2,4]triazole-3-
thiol (6b): To a solution of (4-methoxyphenylamino)acetic acid hy-
drazide (4c) (2.0 g, 10.244 mmol, 1.0 equiv) in EtOH (100 mL) was
added 4-methylphenyl isothiocyanate (1.575 g, 10.244 mmol,
1.0 equiv), and the reaction mixture was heated under reflux for
90 min, and the formation of precipitate was observed. The reac-
tion was cooled, and the white precipitate formed was filtered and
washed with EtOH. To the white precipitate was added aqueous
1.5m KOH (20 mL) and heated at reflux for 30 min, then cooled.
The reaction was neutralised with 5n HCl and diluted with H2O fol-
lowed by extraction with EtOAc. The organic layer was dried
(Na2SO4) and concentrated under reduced pressure. The resulting
pale-yellow solid was washed with EtOH/MeOH (1:1) to afford the
desired product 6b as a pale-white powder (1.444 g, 43% yield):
Rf=0.5 (EtOAc/PE, 3:1) ; mp: 158–160 8C;
1H NMR (400 MHz,
[D6]DMSO): d=13.76 (1H, s, SH or NH), 7.34 (2H, d, J=8.3 Hz, Ar-
H), 7.30 (2H, d, J=8.3 Hz, Ar-H), 6.67 (2H, d, J=8.9 Hz, Ar-H), 6.45
(2H, d, J=8.9 Hz, Ar-H), 5.42 (1H, t, J=5.9/6.0 Hz, NH), 4.02 (2H, d,
J=6.0 Hz, CH2), 3.61 (3H, s, OCH3), 2.38 ppm (3H, s, CH3);
13C NMR
(100.6 MHz, [D6]DMSO): Cq: d=168.1, 151.2, 150.6, 141.7, 139.0,
130.9; CH: 129.8, 127.8, 114.4, 113.5; CH2: 39.4, CH3: 55.2,
20.8 ppm; HRMS (ES): m/z [M+H]+ calcd for C17H19N4OS: 327.1201,
found: 326.9906.
4-(4-Chlorophenyl)-5-(p-tolylaminomethyl)-4H-[1,2,4]triazole-3-
thiol (6c): p-Tolylaminoacetic acid hydrazide (4b) (1.0 g,
5.581 mmol, 1.0 equiv) in EtOH (50 mL) was heated at 70 8C, result-
ing in a clear solution. To this was added 4-chlorophenyl isothio-
cyanate (947 mg, 5.58 mmol, 1.0 equiv), and the formation of
a white precipitate was observed within 2 min. The reaction was al-
lowed to stir for a further 10 min, and the reaction was cooled. The
white precipitate formed was filtered and washed with EtOH. To
the white precipitate was added aqueous 1.0m NaOH (10 mL) and
heated at reflux for 2 h, then cooled. Formation of a pale-white
precipitate was observed. To this was added 25 mL cold H2O and
neutralised with 5n HCl. The resulting white solid was recrystal-
lised with MeOH to afford the desired product 6c as a white crys-
talline solid (209 mg, 22% yield): Rf=0.68 (EtOAc);
1H NMR
(400 MHz, [D6]DMSO): d=7.54 (2H, d, J=8.7 Hz, Ar-H), 7.39 (2H, d,
J=8.7 Hz, Ar-H), 6.83 (2H, d, J=8.1 Hz, Ar-H), 6.41 (2H, d, J=
8.4 Hz, Ar-H), 5.53 (1H, t, J=5.6 Hz, NH), 4.04 (2H, d, J=5.6 Hz,
CH2), 2.12 ppm (3H, s, CH3);
13C NMR (100.6 MHz, [D6]DMSO): Cq:
d=167.8, 149.7, 145.5, 133.7, 133.2, 124.8; CH: 129.9, 129.1, 129.0,
112.4; CH2: 39.1; CH3: 20.0 ppm; HRMS (ES): m/z [M+H]
+ calcd for
C16H16ClN4S: 331.0706, found: 331.0877.
4-Phenyl-5-o-tolyloxymethyl-4H-[1,2,4]triazole-3-thiol (6d): To
a solution of (4a) o-tolyloxyacetic acid hydrazide (2.0 g,
11.095 mmol, 1.0 equiv) in EtOH (100 mL) was added phenyl iso-
thiocyanate (1.356 mL, 11.095 mmol, 1.0 equiv), and the reaction
mixture was heated under reflux for overnight, and the formation
of precipitate was observed. The reaction was cooled, and the
white precipitate formed was filtered and washed with EtOH. To
the white precipitate was added aqueous 1.5m KOH (20 mL) and
heated at reflux for 30 min, then cooled. The reaction was neutral-
ised with 5n HCl. The white precipitate obtained was separated by
filtration and washed further with H2O and freeze dried (2.093 g,
64% yield): Rf=0.30 (EtOAc/PE, 3:1) mp: 217–219 8C;
1H NMR
(400 MHz, [D6]DMSO): d=14.07 (1H, s, SH or NH), 7.60–7.40 (5H,
m, Ar-H), 7.12–7.00 (2H, m, Ar-H), 6.88 (1H, d, J=8.0 Hz, Ar-H), 6.82
(1H, td, J=0.4/0.5, 7.3/7.4 Hz, Ar-H), 5.01 (2H, s, CH2), 1.85 ppm
(3H, s, CH3);
13C NMR (100.6 MHz, [D6]DMSO): Cq: d=168.7, 155.1,
148.1, 133.5, 126.0; CH: 130.6, 129.5, 129.3, 127.9, 126.8, 121.2,
111.5; CH2: 59.9; CH3: 15.6 ppm; HRMS (ES): m/z [M+H]
+ calcd for
C16H16N3OS: 298.0936, found: 298.1035.
4-(2-Ethylphenyl)-5-o-tolyloxymethyl-4H-[1,2,4]triazole-3-thiol
(6e): To a solution of (4a) o-Tolyloxyacetic acid hydrazide (4.0 g,
22.19 mmol, 1.0 equiv) in EtOH (100 mL) was added 2-ethylphenyl
isothiocyanate (3.470 mL, 22.19 mmol, 1.0 equiv), and the reaction
mixture was heated under reflux overnight. The reaction was
cooled and concentrated under reduced pressure, resulting in
a white powder, which was further washed with EtOH/PE (1:3). To
the white powder was added aqueous 1.5m KOH (20 mL) and
heated at reflux for 30 min, then cooled. The reaction was neutral-
ised with 5n HCl. The white precipitate obtained was separated by
filtration and washed further with H2O and freeze dried (6.151 g,
85% yield): Rf=0.25 (EtOAc/PE, 1:3) ; mp: 212–214 8C;
1H NMR
(400 MHz, [D6]DMSO): d=14.12 (1H, s, SH or NH), 7.53–7.40 (2H,
m, Ar-H), 7.39–7.27 (2H, m, Ar-H), 7.12–7.03 (2H, m, Ar-H), 6.90–
6.78 (2H, m, Ar-H), 4.89 (2H, dd, J=13.0, 31 Hz, CH2), 2.48–2.23
(2H, 2 hex, HA & HB of CH2CH3), 1.90 (3H, s, CH3), 1.09 ppm (3H, t,
J=7.6, CH2-CH3) ;
13C NMR (100.6 MHz, [D6]DMSO): Cq: d=168.6,
155.2, 148.2, 141.5, 131.8, 125.9; CH: 130.6, 130.2, 128.6, 128.6,
126.9, 121.2, 111.5; CH2: 59.8, 23.0; CH3: 15.6, 12.9 ppm; HRMS (ES):
m/z [M+H]+ calcd for C18H20N3OS: 326.1249, found: 326.1287.
4-(2-Chlorophenyl)-5-o-tolyloxymethyl-4H-[1,2,4]triazole-3-thiol
(6 f): To a solution of (4a) o-tolyloxyacetic acid hydrazide (2.0 g,
11.09 mmol, 1.0 equiv) in EtOH (100 mL) was added 2-chlorophenyl
isothiocyanate (1.477 mL, 11.09 mmol, 1.0 equiv), and the reaction
mixture was heated under reflux for 10 min; the formation of pre-
cipitate was observed. The reaction was cooled, and the white pre-
cipitate formed was filtered and washed with EtOH. To the white
precipitate was added aqueous 1.5m KOH (30 mL) and heated at
reflux for 30 min, then cooled. The reaction was neutralised with
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5n HCl. The white precipitate obtained was separated by filtration
and washed further with H2O and freeze dried (3.076 g, 84% yield):
Rf=0.57 (EtOAc/PE, 1:1) ; mp: 156–158 8C;
1H NMR (400 MHz,
[D6]DMSO): d=14.16 (1H, s, SH or NH), 7.73–7.66 (1H, m, Ar-H),
7.62–7.47 (3H, m, Ar-H), 7.12–7.02 (2H, m, Ar-H), 6.89 (1H, d, J=
7.9 Hz, Ar-H), 6.82 (1H, td, J=0.7, 7.4 Hz, Ar-H), 4.96 (2H, dd, J=
13.1, 29.7 Hz, CH2), 1.90 ppm (3H, s, CH3);
13C NMR (100.6 MHz,
[D6]DMSO): Cq: d=168.8, 155.1, 147.9, 132.2, 140.0, 125.8; CH:
131.8, 130.7, 130.6, 130.2, 128.4, 126.8, 121.2, 111.3; CH2: 59.8; CH3:
15.6 ppm; HRMS (ES): m/z [M+H]+ calcd for C16H15ClN3OS:
332.0546, found: 332.0588.
4-(2-Methoxyethyl)-5-o-tolyloxymethyl-4H-[1,2,4]triazole-3-thiol
(6g): To a solution of (4a) o-tolyloxyacetic acid hydrazide (2.0 g,
11.09 mmol, 1.0 equiv) in EtOH (100 mL) was added 2-methoxyeth-
yl isothiocyanate (1.203 mL, 11.09 mmol, 1.0 equiv), and the reac-
tion mixture was heated under reflux overnight. The reaction was
cooled, and the white precipitate formed was filtered and washed
with EtOH. To the white precipitate was added aqueous 1.5m KOH
(30 mL) and heated at reflux for 30 min, then cooled. The reaction
was neutralised with 5n HCl. The white precipitate obtained was
separated by filtration and washed further with H2O and freeze
dried (2.787 g, 90% yield): Rf=0.13 (EtOAc/PE, 1:3) ; mp: 162–
164 8C; 1H NMR (400 MHz, [D6]DMSO): d=13.91 (1H, s, SH or NH),
7.22–7.14 (2H, m, Ar-H), 7.07 (1H, d, J=8.0 Hz, Ar-H), 6.90 (1H, td,
J=0.8, 7.3 Hz, Ar-H), 5.21 (2H, s, CH2), 4.21 (2H, t, J=5.5 Hz, CH2),
3.62 (2H, t, J=5.5 Hz, CH2), 3.22 (3H, s, OCH3), 2.15 ppm (3H, s,
CH3);
13C NMR (100.6 MHz, [D6]DMSO): Cq: d=167.4, 155.4, 148.7,
126.0; CH: 130.7, 127.0, 121.3, 111.8; CH2: 68.6, 60.1, 43.4; CH3:
58.4, 15.9 ppm; HRMS (ES): m/z [M+H]+ calcd for C13H18N3O2S:
280.1041, found: 280.1116.
4-(4-Chlorophenyl)-5-o-tolyloxymethyl-4H-[1,2,4]triazole-3-thiol
(6h): To a solution of (4a) o-tolyloxyacetic acid hydrazide (2.5 g,
13.872 mmol, 1.0 equiv) in EtOH (100 mL) at 80 8C was added 4-
chlorophenyl isothiocyanate (2.376 g, 13.872 mmol, 1.0 equiv), and
almost immediately formation of the precipitate was observed. The
reaction mixture was heated under reflux for 10 min, and the reac-
tion was cooled. The white precipitate formed was filtered and
washed with EtOH. To the white precipitate was added aqueous
1.5m KOH (47 mL) and heated at reflux for 30 min, then cooled.
The reaction was neutralised with 5n HCl. The white precipitate
obtained was separated by filtration and washed further with dis-
tilled H2O and freeze dried (4.095 g, 89% yield): Rf=0.20 (EtOAc/
PE, 1:3) ; mp: 152–154 8C; 1H NMR (400 MHz, [D6]DMSO): d=14.11
(1H, s, SH or NH), 7.60 (2H, d, J=8.8 Hz, Ar-H), 7.51 (2H, d, J=
8.8 Hz, Ar-H), 7.14–7.03 (2H, m, Ar-H), 6.90 (1H, d, J=7.9 Hz, Ar-H),
6.83 (1H, td, J=0.7, 7.4 Hz, Ar-H), 5.04 (2H, s, CH2), 1.85 ppm (3H,
s, CH3);
13C NMR (100.6 MHz, [D6]DMSO): Cq: d=168.7, 155.0, 148.1,
134.2, 132.5, 125.9; CH: 130.6, 129.9, 129.3, 126.8, 121.2, 111.6; CH2:
59.9; CH3: 15.5 ppm; HRMS (ES): m/z [M+H]
+ calcd for
C16H15ClN3OS: 332.0546, found: 332.0685.
4-p-Tolyl-5-o-tolyloxymethyl-4H-[1,2,4]triazole-3-thiol (6 i): To a so-
lution of (4a) o-tolyloxyacetic acid hydrazide (2.5 g, 13.872 mmol,
1.0 equiv) in EtOH (100 mL) was added 4-methylphenyl isothiocya-
nate (2.134 g, 13.872 mmol, 1.0 equiv), and the reaction mixture
was heated under reflux for 1 h; the formation of precipitate was
observed. The reaction was cooled, and the white precipitate
formed was filtered, washed with EtOH. To the white precipitate
was added aqueous 1.5m KOH (30 mL) and heated at reflux for
30 min, then cooled. The reaction was neutralised with 5n HCl.
The white precipitate obtained was separated by filtration and
washed further with H2O and freeze dried (3.631 g, 84%): Rf=0.17
(EtOAc/PE, 1:3) mp: 177–179 8C; 1H NMR (400 MHz, [D6]DMSO): d=
14.04 (1H, s, SH or NH), 7.35–7.26 (4H, m, Ar-H), 7.04–7.12 (2H, m,
Ar-H), 6.88 (1H, d, J=7.9 Hz, Ar-H), 6.83 (1H, td, J=0.6, 7.4 Hz, Ar-
H), 4.97 (2H, s, CH2), 2.35 (3H, s, CH3), 1.90 ppm (3H, s, CH3);
13C NMR (100.6 MHz, [D6]DMSO): Cq: d=168.7, 155.1, 148.2, 139.2,
130.9, 126.0; CH: 130.6, 129.7, 127.7, 126.9, 121.2, 111.6; CH2: 59.9;
CH3: 20.7, 15.7 ppm; HRMS (ES): m/z [M+H]
+ calcd for C17H18N3OS:
312.1092, found: 312.1252.
4-(4-Methoxyphenyl)-5-o-tolyloxymethyl-4H-[1,2,4]triazole-3-
thiol (6 j): To a solution of (4a) o-tolyloxyacetic acid hydrazide
(2.138 g, 11.86 mmol, 1.0 equiv) in EtOH (100 mL) was added 4-me-
thoxyphenyl isothiocyanate (1.690 mL, 11.86 mmol, 1.0 equiv), and
the reaction mixture was heated under reflux for 5 h. The reaction
was cooled, and the white precipitate formed was filtered, washed
with EtOH. To the white precipitate was added aqueous 1.5m KOH
(30 mL) and heated at reflux for 30 min, then cooled. The reaction
was neutralised with 5n HCl. The white precipitate obtained was
separated by filtration and washed further with H2O and freeze
dried (1.238 g, 32% yield): Rf=0.18 (EtOAc/PE, 1:1) ; mp: 155–
157 8C; 1H NMR (400 MHz, [D6]DMSO): d=14.02 (1H, s, SH or NH),
7.36 (2H, d, J=9.0 Hz, Ar-H), 7.12–7.02 (4H, m, Ar-H), 6.90 (1H, d,
J=7.9 Hz, Ar-H), 6.87–6.80 (1H, m, Ar-H), 4.97 (2H, s, CH2), 3.79
(3H, s, OCH3), 1.92 ppm (3H, s, CH3);
13C NMR (100.6 MHz,
[D6]DMSO): Cq: d=168.9, 159.7, 155.2, 148.4, 126.0; CH: 130.6,
129.2, 126.9, 121.2, 114.4, 111.6; CH2: 59.9; CH3: 55.5, 15.7 ppm;
HRMS (ES): m/z [M+H]+ calcd for C17H18N3O2S: 328.1041, found:
328.1217.
4-(4-Isopropylphenyl)-5-o-tolyloxymethyl-4H-[1,2,4]triazole-3-
thiol (6k): The procedure was similar to that for 6 j, except that 4-
isopropylphenyl isothiocyanate (2.00 mL, 11.095 mmol, 1.0 equiv)
was used. Product 6k was isolated as a white powder (1.914 g,
51% yield): Rf=0.61 (EtOAc/PE, 1:1) ; mp: 168–170 8C;
1H NMR
(400 MHz, [D6]DMSO): d=14.04 (1H, s, SH or NH), 7.44–7.32 (4H,
m, Ar-H), 7.11–7.00 (2H, m, Ar-H), 6.86 (1H, d, J=7.9 Hz, Ar-H), 6.82
(1H, td, J=0.7, 7.3 Hz, Ar-H), 5.03 (2H, s, CH2), 3.04–2.84 (1H, hept,
CH of isopropyl), 1.81 (3H, s, CH3), 1.21 ppm (6H, d, J=6.9 Hz,
(CH3)2 of isopropyl) ;
13C NMR (100.6 MHz, [D6]DMSO): Cq: d=168.6,
155.1, 149.6, 148.3, 131.2, 126.1; CH: 130.5, 127.5, 127.1, 126.8,
121.2, 111.7, 33.2; CH2: 60.0; CH3: 23.7, 15.5 ppm; HRMS (ES): m/z
[M+H]+ calcd for C19H22N3OS: 340.1405, found: 340.1575.
Library synthesis : The analogues of 1,2,4-triazole target com-
pounds (1b–c, 7a–i except 7h) were synthesised using a 12-well
Radley’s parallel synthesiser.
2-(4-Phenyl-5-o-tolyloxymethyl-4H-[1,2,4]triazol-3-ylsulfanyl)ace-
tamide (7a): A solution of product 6d (446 mg, 1.5 mmol,
1.0 equiv) in DMF (4 mL), and a solution of 2-bromoacetamide
(211 mg, 1.5 mmol, 1.0 equiv) in DMF (2 mL) were both added sep-
arately to a dry Radley’s reaction tube containing K2CO3 (249 mg,
1.8 mmol, 1.2 equiv). The reaction mixture was allowed to stir at
45 8C overnight in a Radley’s parallel synthesiser. The reaction mix-
ture was poured onto crushed ice (50 mL) and allowed to stand for
~3 h. The precipitate formed was collected by filtration, washed
thoroughly with H2O to remove DMF then freeze dried, followed
by recrystallisation from EtOH/Et2O. Product 7a was obtained as
a pale-yellow crystalline solid (232 mg, 44% yield): Rf=0.28 (EtOAc/
MeOH, 9:1) ; mp: 123–125 8C; 1H NMR (400 MHz, [D6]DMSO): d=
7.68 (1H, bs OH), 7.60–7.46 (5H, m, Ar-H), 7.25 (1H, bs, NH), 7.12–
7.02 (2H, m, Ar-H), 6.96 (1H, d, J=7.8 Hz, Ar-H), 6.81 (1H, td, J=
0.8, 7.3/7.4 Hz, Ar-H), 5.13 (2H, s, CH2), 3.95 (2H, s CH2), 1.82 ppm
(3H, s, CH3);
13C NMR (100.6 MHz, [D6]DMSO): Cq: d=168.5, 155.3,
151.8, 151.7, 132.8, 125.9; CH: 130.5, 130.0, 129.8, 126.8, 126.8,
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121.0, 111.6; CH2: 59.7, 35.9; CH3: 15.6 ppm; HRMS (ES): m/z [M+
H]+ calcd for C18H19N4O2S: 355.1150, found: 355.1118.
2-[4-(2-Ethylphenyl)-5-o-tolyloxymethyl-4H-[1,2,4]triazol-3-ylsul-
fanyl]acetamide (1b): The procedure was similar to that for 7a
except that product 6e (325.5 mg, 1.0 mmol, 1.0 equiv) was used
and the recrystallisation was carried out from EtOH. Product 1b
was isolated as a white powder (147 mg, 39% yield): Rf=0.34
(EtOAc/MeOH, 9:1) ; mp: 134–136 8C; 1H NMR (400 MHz, [D6]DMSO):
d=7.68 (1H, bs, OH), 7.58–7.46 (3H, m, Ar-H), 7.43–7.37 (1H, m,
Ar-H), 7.34 (1H, dd, J=1.4, 7.7 Hz; Ar-H), 7.24 (1H, bs,=NH), 7.12–
7.04 (2H, m, Ar-H), 6.95 (1H, d, J=7.9 Hz, Ar-H), 6.81 (1H, td, J=
0.8, 7.3/7.4 Hz, Ar-H), 5.00 (2H, dd, J=12.7, 41.9 Hz, CH2), 3.97 (2H
d, J=2.0 Hz, CH2), 2.33–2.18 (2H, m, CH2CH3), 1.89 (3H, s, CH3),
1.06 ppm (3H, t, J=7.5 Hz, CH2CH3) ;
13C NMR (100.6 MHz,
[D6]DMSO): Cq: d=168.4, 155.5, 152.3, 151.7, 140.9, 125.8; CH:
130.9, 130.6, 129.1, 128.2, 127.3, 126.9, 121.1, 111.5; CH2: 59.6, 35.7,
22.7; CH3: 15.7, 13.3 ppm; HRMS (ES): m/z [M+H]
+ calcd for
C20H23N4O2S: 383.1463, found: 383.1430.
2-[4-(2-Chlorophenyl)-5-o-tolyloxymethyl-4H-[1,2,4]triazol-3-yl-
sulfanyl]acetamide (7b): The procedure was similar to that for 7a
except that product 6 f (332 mg, 1.0 mmol, 1.0 equiv) was used,
and the precipitate obtained was washed with EtOH. Product 7b
was isolated as a white crystalline solid (105 mg, 26% yield): Rf=
0.30 (EtOAc/MeOH, 9:1) ; mp: 139–141 8C; 1H NMR (400 MHz,
[D6]DMSO): d=7.75 (1H, dd, J=1.4, 8.0 Hz, Ar-H), 7.70–7.65 (2H, m,
OH & Ar-H), 7.61 (1H, td, J=1.8/1.9, 7.6/7.8 Hz, Ar-H), 7.55 (1H, td,
J=1.5, 7.6 Hz, Ar-H), 7.26 (1H, bs,=NH), 7.12–7.02 (2H, m, Ar-H),
6.96 (1H, d, J=7.7 Hz, Ar-H), 6.80 (1H, td, J=0.8, 7.3 Hz, Ar-H), 5.10
(2H, dd, J=12.9, 36.8 Hz, CH2), 3.95 (2H, dd, J=14.9, 22.0 Hz, CH2),
1.85 ppm (3H, s, CH3);
13C NMR (100.6 MHz, [D6]DMSO): Cq: d=
168.3, 155.3, 152.1, 151.6, 131.4, 130.2, 125.8; CH: 132.3, 130.5,
130.5, 130.0, 128.7, 126.8, 121.0, 111.3; CH2: 59.7, 36.3; CH3:
15.6 ppm; HRMS (ES): m/z [M+H]+ calcd for C18H18ClN4O2S:
389.0761, found: 389.0720.
2-[4-(2-Methoxyethyl)-5-o-tolyloxymethyl-4H-[1,2,4]triazol-3-yl-
sulfanyl]acetamide (7c): The procedure was similar to the proce-
dure for 7a except that product 6g (419 mg, 1.5 mmol, 1.0 equiv)
was used and the precipitate obtained was washed with EtOH/
MeOH (5:1). Product 7c was isolated as a white powder (325 mg,
64% yield): Rf=0.22 (EtOAc/MeOH, 9:1) ; mp: 170–172 8C;
1H NMR
(400 MHz, [D6]DMSO): d=7.66 (1H, bs, OH), 7.22 (1H, bs,=NH),
7.21–7.10 (3H, m, Ar-H), 6.92–6.86 (1H, m, Ar-H), 5.27 (2H, s, CH2),
4.24 (2H, t, J=5.3 Hz, CH2), 3.91 (2H, s, CH2), 3.60 (2H, t, J=5.3 Hz,
CH2), 3.20 (3H, s, OCH3), 2.14 ppm (3H, s, CH3);
13C NMR
(100.6 MHz, [D6]DMSO): Cq: d=168.7, 155.6, 151.9, 151.3, 125.9;
CH: 130.7, 127.0, 121.1, 111.9; CH2: 70.1, 60.1, 43.8, 36.9; CH3: 58.4,
16.0 ppm; HRMS (ES): m/z [M+H]+ calcd for C15H21N4O3S:
337.1256, found: 337.1235.
2-(4-p-Tolyl-5-o-tolyloxymethyl-4H-[1,2,4]triazol-3-ylsulfanyl)ace-
tamide (7d): The procedure was similar to that for 7a except that
product 6 i (467 mg, 1.5 mmol, 1.0 equiv) was used and the recrys-
tallisation was carried out from EtOH. Product 7d was isolated as
a white needle-like crystalline solid (224 mg, 41% yield): Rf=0.28
(EtOAc/MeOH, 9:1) ; mp: 136–138 8C; 1H NMR (400 MHz, [D6]DMSO):
d=7.68 (1H, bs, OH), 7.41–7.33 (4H, m, Ar-H), 7.24 (1H, bs,=NH),
7.14–7.02 (2H, m, Ar-H), 6.96 (1H, d, J=7.9 Hz, Ar-H), 6.82 (1H, td,
J=0.8, 7.3 Hz, Ar-H), 5.09 (2H, s, CH2), 3.94 (2H, s, CH2), 2.36 (3H, s,
CH3), 1.88 ppm (3H, s, CH3);
13C NMR (100.6 MHz, [D6]DMSO): Cq:
d=168.5, 155.4, 152.0, 151.7, 139.9, 130.1, 125.9; CH: 130.5, 130.2,
126.9, 126.6, 121.0, 111.6; CH2: 59.6, 35.9; CH3: 20.7, 15.7 ppm;
HRMS (ES): m/z [M+H]+ calcd for C19H21N4O2S: 369.1307, found:
369.1411.
2-[4-(4-Chlorophenyl)-5-o-tolyloxymethyl-4H-[1,2,4]triazol-3-yl-
sulfanyl]acetamide (7e): The procedure was similar to that for 7a
except that product 6h (497.7 mg, 1.5 mmol, 1.0 equiv) was used
and the precipitate obtained was washed with EtOH/MeOH (3:1).
Product 7e was isolated as a white crystalline solid (481 mg, 83%
yield): Rf=0.26 (EtOAc/MeOH, 9:1) ; mp: 191–193 8C;
1H NMR
(400 MHz, [D6]DMSO): d=7.67 (1H, bs, OH), 7.65 (2H, d, J=8.8 Hz,
Ar-H), 7.57 (2H, d, J=8.8 Hz, Ar-H), 7.25 (1H, bs,=NH), 7.13–7.03
(2H, m, Ar-H), 6.97 (1H, d, J=7.9 Hz, Ar-H), 6.82 (1H, td, J=0.6,
7.3/7.4 Hz, Ar-H), 5.15 (2H, s, CH2), 3.94 (2H, s, CH2), 1.84 ppm (3H,
s, CH3);
13C NMR (100.6 MHz, [D6]DMSO): Cq: d=168.4, 155.3, 151.8,
151.7, 134.7, 131.7, 125.8; CH: 130.5, 129.8, 128.8, 126.9, 121.1,
111.6; CH2: 59.7, 36.1; CH3: 15.6 ppm; HRMS (ES): m/z [M+H]
+
calcd for C18H18ClN4O2S: 389.0761, found: 389.0978.
2-[4-(4-Methoxyphenyl)-5-o-tolyloxymethyl-4H-[1,2,4]triazol-3-yl-
sulfanyl]acetamide (7 f): The procedure was similar to that for 7a
except that product 6 j (491 mg, 1.5 mmol, 1.0 equiv) was used
and the recrystallisation was carried out from EtOH. Product 7 f
was isolated as a white powder (135 mg, 24% yield): Rf=0.24
(EtOAc/MeOH, 9:1) ; mp: 135–137 8C; 1H NMR (400 MHz, [D6]DMSO):
d=7.68 (1H, bs, OH), 7.41 (2H, d, J=9.0 Hz, Ar-H), 7.24 (1H, bs,=
NH), 7.13–7.04 (4H, m, Ar-H), 6.97 (1H, d, J=7.8 Hz, Ar-H), 6.82
(1H, td, J=0.7, 7.3 Hz, Ar-H), 5.08 (2H, s, CH2), 3.93 (2H, s, CH2),
3.80 (3H, s, OCH3), 1.90 ppm (3H, s, CH3);
13C NMR (100.6 MHz,
[D6]DMSO): Cq: d=168.5, 160.1, 155.4, 152.3, 151.9, 125.9, 125.1;
CH: 130.5, 128.3, 126.9, 121.0, 114.9, 111.6; CH2: 59.7, 35.8; CH3:
55.6, 15.8 ppm; HRMS (ES): m/z [M+H]+ calcd for C19H21N4O3S:
385.1256, found: 385.1466.
2-[4-(4-Isopropylphenyl)-5-o-tolyloxymethyl-4H-[1,2,4]triazol-3-
ylsulfanyl]acetamide (7g): The procedure was similar to that for
7a except that product 6k (339.5 mg, 1.0 mmol, 1.0 equiv) was
used and the recrystallisation was carried out from EtOH/Et2O.
Product 7g was isolated as a white crystalline solid (300 mg, 76%
yield): Rf=0.30 (EtOAc/MeOH, 9:1) ; mp: 135–137 8C;
1H NMR
(400 MHz, [D6]DMSO): d=7.69 (1H, bs, OH), 7.47–7.36 (4H, m, Ar-
H), 7.25 (1H, bs,=NH), 7.02–7.12 (2H, m, Ar-H), 6.95 (1H, d, J=
7.8 Hz, Ar-H), 6.81 (1H, td, J=0.8, 7.3/7.4 Hz, Ar-H), 5.14 (2H, s,
CH2), 3.95 (2H, s, CH2), 2.96 (1H, hep, CH of isopropyl), 1.80 (3H, s,
CH3), 1.21 ppm (6H, d, J=6.9 Hz, (CH3)2 of isopropyl) ;
13C NMR
(100.6 MHz, [D6]DMSO): Cq: d=168.5, 155.3, 151.9, 151.8, 150.3,
126.0; CH: 130.5, 127.6, 126.8, 126.5, 121.0, 111.7, 33.2; CH2: 59.8,
35.9; CH3: 23.6, 15.6 ppm; HRMS (ES): m/z [M+H]
+ calcd for
C21H25N4O2S: 397.1620, found: 397.1510.
2-[4-(4-Chlorophenyl)-5-(p-tolylaminomethyl)-4H-[1,2,4]triazol-3-
ylsulfanyl]acetamide (7h): To a solution of 4-(4-chlorophenyl)-5-(p-
tolylaminomethyl)-4H-[1,2,4]triazole-3-thiol (6c ; 200 mg,
0.604 mmol, 1.0 equiv) in acetone (7 mL) was added added 2-bro-
moacetamide (83.0 mg, 0.604 mmol, 1.0 equiv) and K2CO3 (100 mg,
0.725 mmol, 1.2 equiv). The reaction mixture was allowed to stir at
45 8C for 4 h. The reaction mixture was evaporated under reduced
pressure. The residue was diluted with H2O and extracted with
EtOAc. Then EtOAc layer was dried (Na2SO4) and concentrated
under reduced pressure. Purification of the residue by column
chromatography [CH2Cl2/MeOH (5%)] gave product 7h as a pale-
yellow crystalline solid (41 mg, 17% yield): Rf=0.19 (EtOAc/MeOH,
9:1) ; mp: 170–172 8C; 1H NMR (400 MHz, [D6]DMSO): d=7.66 (1H,
bs, OH), 7.63 (2H, d, J=8.7 Hz, Ar-H), 7.48 (2H, d, J=8.7 Hz, Ar-H),
7.23 (1H, bs,=NH), 6.83 (2H, d, J=8.2 Hz, Ar-H), 6.42 (2H, d, J=
8.4 Hz, Ar-H), 5.65 (1H, t, J=5.6 Hz, NH), 4.19 (2H, d, J=5.6 Hz,
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CH2), 3.88 (2H, s, CH2), 2.12 ppm (3H, s, CH3);
13C NMR (100.6 MHz,
[D6]DMSO): Cq: d=168.5, 154.0, 150.6, 145.6, 134.6, 131.8, 124.9;
CH: 129.8, 129.2, 129.0, 112.4; CH2: 38.4, 36.1; CH3: 20.1 ppm;
HRMS (ES): m/z [M+H]+ calcd for C18H19ClN5OS: 388.0921, found:
388.1184.
2-[5-[(4-Methoxyphenylamino)methyl]-4-p-tolyl-4H-[1,2,4]triazol-
3-ylsulfanyl]acetamide (1c): The procedure was similar to that for
7a except that product 6b (200 mg, 0.612 mmol, 1.0 equiv) was
used and the recrystallisation was carried out from EtOH. Product
1c was isolated as a white powder (147 mg, 63% yield): Rf=0.16
(EtOAc/MeOH, 9:1) ; mp: 157–159 8C; 1H NMR (400 MHz, [D6]DMSO):
d=7.65 (1H, bs, OH), 7.37 (2H, d, J=8.2 Hz, Ar-H), 7.33 (2H, d, J=
8.5 Hz, Ar-H), 7.21 (1H, bs,=NH), 6.66 (2H, d, J=8.9 Hz, Ar-H), 6.49
(2H, d, J=9.0 Hz, Ar-H), 5.44 (1H, t, J=5.7 Hz, NH), 4.13 (2H, d, J=
5.7 Hz, CH2), 3.88 (2H, s, CH2), 3.61 (3H, s, OCH3), 2.39 ppm (3H, s,
CH3);
13C NMR (100.6 MHz, [D6]DMSO): Cq: d=168.6, 154.0, 151.2,
150.7, 142.1, 139.7, 130.3; CH: 130.2, 126.8, 114.4, 113.5; CH2: 38.9,
35.9; CH3: 55.3, 20.8 ppm; HRMS (ES): m/z [M+H]
+ calcd for
C19H22N5O2S: 384.1416, found: 384.1509.
2-[4-(2-Ethylphenyl)-5-[(4-methoxyphenylamino)methyl]-4H-
[1,2,4]triazol-3-ylsulfanyl]acetamide (7 i): The procedure was simi-
lar to that for 7a except that product 6a (340.5 mg, 1.0 mmol,
1.0 equiv) was used and the recrystallisation was carried out from
EtOH. Product 7 i was isolated as a white crystalline solid (222 mg,
56% yield): Rf=0.3 (EtOAc/MeOH, 9:1) ; mp: 134–136 8C;
1H NMR
(400 MHz, [D6]DMSO): d=7.65 (1H, bs, OH), 7.57–7.46 (4H, m, Ar-
H), 7.21 (1H, bs,=NH), 6.65 (2H, d, J=9.0 Hz, Ar-H), 6.48 (2H, d,
J=9.0 Hz, Ar-H), 5.40 (1H, t, J=5.7/5.8 Hz, NH), 3.91 (2H, d, J=
1.9 Hz, CH2), 3.61 (3H, s, OCH3), 2.21 (2H, q, J=7.6 Hz, -CH2CH3),
1.03 ppm (3H, t, J=7.5 Hz, -CH2CH3) ;
13C NMR (100.6 MHz,
[D6]DMSO): Cq: d=168.5, 154.1, 151.2, 151.0, 142.1, 141.1, 131.0;
CH: 130.6, 129.3, 128.1, 127.2, 114.4, 113.4; CH2: 38.9, 35.7, 22.8;
CH3: 55.2, 13.6 ppm; IR (KBr): n˜=3384 (NH), 3154 (CH of Ar), 2977,
2831 (CH from CH2), 1666 (C=O), 1517 cm
1(C=N); HRMS (ES): m/z
[M+H]+ calcd for C20H24N5O2S: 398.1572, found: 398.1344.
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